Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Her2/neu induces all-transretinoic acid (ATRA) resistance in breast cancer cells

Abstract

We observed that all-trans retinoic acid (ATRA) inhibited the growth of MCF-7 breast cancer cells, but not those transfected with HER2/NEUor its transactivating ligand HEREGULIN. This suggests that Her2/neu causes breast cancer cells to be resistant to the growth inhibitory effects of ATRA. To confirm this observation, MDA-MB-453 and BT-474 cells, which have high levels of Her2/neu and are resistant to ATRA, were incubated with the trastuzumab (Herceptin™) antibody so that we could determine whether inhibition of the expression and function of Her2/neu would resensitize these cells to ATRA. Indeed, we found that MDA-MB-453 and BT-474 cells treated with trastuzumab were growth inhibitory by ATRA. We then determined whether Her2/neu uses Grb2 and Akt proteins to induce ATRA resistance. Liposome-incorporated Grb2 antisense oligonucleotides (L-Grb2) and a dominant negative (DN) AKTmutant were used to down-regulate Grb2 expression and inhibit Akt activity, respectively. When incubated with L-Grb2 or transfected with the DN AKTmutant, ATRA-resistant, Her2/neu-overexpressing cells became sensitive to ATRA. Our results indicate that Her2/neu utilizes Grb2 and Akt proteins to induce ATRA resistance in breast cancer cells. ATRA sensitivity was also correlated with RARα protein levels since higher RARα protein levels were observed in cells in which the Her2/neu pathway was inhibited.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  • Alessi D, Andjelkovic M, Caudwell F, Cron P, Morrice N, Cohen P, Hemmings B . 1996 EMBO J. 15: 6541–6551

  • Baselga J, Norton L, Albanell J, Kim Y-M, Mendelsohn J . 1998 Cancer Res. 58: 2825–2831

  • Bellacosa A, de Feo D, Godwin A, Bell D, Cheng J, Altomare D, Wan M, Dubeau L, Scambia G, Masciullo V . 1995 Int. J. Cancer 64: 280–285

  • Benz C, Scott G, Sarup J, Johnson R, Tripathy D, Coronado E, Shepard H, Osborne C . 1992 Breast Cancer Res. Treatment 24: 85–95

  • Burgering B, Coffer P . 1995 Nature 376: 599–602

  • Carter C, Shaw B . 2000 Exp. Mol. Pathol. 68: 170–186

  • Carter P, Presta L, Gorman C, Ridgway J, Henner D, Wong W, Rowland A, Kotts C, Carver M, Shepard H . 1992 Proc. Natl. Acad. Sci. USA 89: 4285–4289

  • De Luca L, Scita G, Takatsuka J . 1997 J. Cell Physiol. 173: 297–300

  • Dow R, Hendley J, Pirkmaier A, Musgrove EA, Germain D . 2001 J. Biol. Chem. 276: 45945–45951

  • Fitzgerald P, Teng M, Chandraratna R, Heyman R, Allegretto E . 1997 Cancer Res. 57: 2642–2650

  • Fontana J . 1987 Exp. Cell Biol. 55: 136–144

  • Fraker L, Halter S, Forbes J . 1984 Cancer Res. 44: 5757–5762

  • Franke T, Yang S, Chan T, Datta K, Kazlauskas A, Morrison D, Kaplan D, Tsichlis P . 1995 Cell 81: 727–736

  • Galang CK, Garcia-Ramirez J, Solski PA, Westwick JK, Der CJ, Neznanov NN, Oshima RG, Hauser CA . 1996 J. Biol. Chem. 271: 7992–7998

  • Hoi Sang U, Espiritu OD, Kelley PY, Klauber MR, Hatton JD . 1995 J. Neurosurg. 82: 841–846

  • Hudziak R, Lewis G, Winget M, Fendly B, Shepard M, Ullrich A . 1989 Mol. Cell. Biol. 9: 1165–1172

  • Kern F, McLeskey S, Zhang L, Kurebayashi J, Liu Y, Ding I, Kharbanda S, Chen D, Miller D, Cullen Kea . 1994 Breast Cancer Res. Treat. 31: 153–165

  • Lenferink AE, Busse D, Flanagan WM, Yakes FM, Arteaga CL . 2001 Cancer Res. 61: 6583–6591

  • Levkowitz G, Klapper LN, Tzahar E, Freywald A, Sela M, Yarden Y . 1996 Oncogene 12: 1117–1125

  • Lim S-J, Lopez-Berestein G, Hung M-C, Lupu R, Tari A . 2000 Oncogene 19: 6271–6276

  • Lotan R . 1979 Cancer Res. 39: 1014–1019

  • Lowenstein E, Daly R, Batzer A, Li W, Margolis B, Lammers R, Ullrich A, Skolnik E, Bar-Sagi D, Schlessinger J . 1992 Cell 70: 431–442

  • Lupu R, Colomer R, Kannan B, Lippman M . 1992 Proc. Natl. Acad. Sci. USA 89: 2287–2291

  • Mangelsdorf D, Umesono K, Evans R . 1994 The retinoids: biology, chemistry and medicine Sporn M, Roberts A and Goodman D (eds) New York: Raven Press pp 319–350

    Google Scholar 

  • Mangiarotti R, Danova M, Alberici R, Pellicciari C . 1998 Br. J. Cancer 77: 186–191

  • Meyers S, LaBudda K, McGlade J, Hayman M . 1994 Mol. Cell. Biol. 14: 3253–3262

  • Miller DL, el-Ashry D, Cheville AL, Liu Y, McLeskey SW, Kern FG . 1994 Cell Growth Differ. 5: 1263–1274

  • Muller A, Nakagawa H, Rustgi A . 1997 Cancer Lett. 113: 95–101

  • Muthuswamy S, Gilman M, Brugge J . 1999 Mol. Cell Biol. 19: 6845–6857

  • Muthuswamy SK, Li D, Lelievre S, Bissell MJ, Brugge JS . 2001 Nat. Cell. Biol. 3: 785–792

  • Peles E, Bacus S, Koski R . 1992 Cell 69: 205–216

  • Pietras R, Fendly B, Chazin V, Pegram M, Howell S, Slamon D . 1994 Oncogene 9: 1829–1838

  • Plowman G, Green J, Culouscou J-M, Rothwell V, Buckley S . 1993 Nature 366: 473–475

  • Rishi A, Gerald T, Shao Z, Li X, Baumann R, Dawson M, Fontana J . 1996 Cancer Res. 56: 5246–5252

  • Roulier S, Rochette-Egly C, Rebit-Bonneton D, Porquet D, Evain-Brion D . 1994 Mol. Cell. Endocrinol. 105: 165–173

  • Sah J, Eckert R, Chandraratna R, Rorke E . 2002 J. Biol. Chem. 277: 9728–9735

  • Schneider S, Offterdinger M, Huber H, Grunt T . 2000 Cancer Res. 60: 5479–5487

  • Sheikh M, Shao Z, Chen J, Hussain A, Jetten A, Fontana J . 1993 J. Cell. Biochem. 53: 394–404

  • Sheikh M, Shao Z, Li X, Dawson M, Jennen A, Wu S, Conley B, Garcia M, Rochefort H, Fontana J . 1994 J. Biol. Chem. 269: 21440–21447

  • Slamon D, Clark M, Wong S, Levin W, Ullrich A, McAuire W . 1987 Science 235: 177–181

  • Sliwkowski M, Lofgren J, Lewis G, Hotaling T, Fendly B, Fox J . 1999 Semin. Oncol. 26: 60–70

  • Sliwkowski M, Schaefer G, Akita R, Lofgren J, Fitzpatrick V, Nuijens A, Fendly B, Cerione R, Vandlen R, Carraway K . 1994 J. Biol. Chem. 269: 14661–14665

  • Steck P, Pershouse M, Jasser S, Yung W, Lin H, Ligon A, Langford L, Baumgard M, Hattier T, Davis T, Frye C, Hu R, Swedlund B, Teng D, Tavtigian S . 1997 Nat. Genet. 15: 356–362

  • Tang C, Perez C, Grunt T, Waibel C, Cho C, Lupu R . 1996 Cancer Res. 56: 3350–3358

  • Tari A, Hung M-C, Li K, Lopez-Berestein G . 1999 Oncogene 18: 1325–1332

  • Tari A, Lopez-Berestein G . 2000 Int. J. Cancer 86: 295–297

  • Toma S, Isnardi L, Raffo P, Dastoli G, De Francisci E, Riccardi L, Palumbo R, Bollag W . 1997 Int. J. Cancer 70: 619–627

  • Toma S, Isnardi L, Riccardi L, Bollag W . 1998 Anticancer Res. 18: 935–942

  • van der Leede B, Folkers G, van den Brink C, van der Saag P, van der Burg B . 1995 Mol. Cell. Endocrinol. 109: 77–86

  • Wilcken N, Sarcevic B, Musgrove E, Sutherland R . 1996 Cell Growth Differ. 7: 65–74

  • Xie Y, Pendergast A, Hung M-C . 1995 J. Biol. Chem. 270: 30717–30724

  • Xing X, Wang S, Xia W, Zou Y, Shao R, Kwong K, Yu Z, Zhang S, Miller S, Huang L, Hung M . 2000 Nat. Med. 6: 189–195

  • Yang HY, Zhou BP, Hung MC, Lee MH . 2000 J. Biol. Chem. 275: 24735–24739

  • Yang L, Kim H, Munoz-Medellin D, Reddy P, Brown P . 1997 Cancer Res. 57: 4652–4661

  • Yu D, Hamada J, Zhang H, Nicolson G, Hung M-C . 1992 Oncogene 7: 2263–2270

  • Yu D, Liu B, Tan M, Junzhi L, Wang S-S, Hung M-C . 1996 Oncogene 13: 1359–1365

  • Zhang L, Bewick M, Lafrenie RM . 2002 Lab. Invest. 82: 71–78

  • Zhou BP, Hu MC, Miller SA, Yu Z, Xia W, Lin SY, Hung M-C . 2000 J. Biol. Chem. 275: 8027–8031

  • Zrihan-Licht S, Lim J, Keydar I, Sliwkowski MX, Groopman JE, Avraham H . 1997 J. Biol. Chem. 272: 1856–1863

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tari, A., Lim, SJ., Hung, MC. et al. Her2/neu induces all-transretinoic acid (ATRA) resistance in breast cancer cells. Oncogene 21, 5224–5232 (2002). https://doi.org/10.1038/sj.onc.1205660

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1205660

Keywords

This article is cited by

Search

Quick links